Literature DB >> 15633014

Antibodies as defensive enzymes.

Sudhir Paul1, Yasuhiro Nishiyama, Stephanie Planque, Sangeeta Karle, Hiroaki Taguchi, Carl Hanson, Marc E Weksler.   

Abstract

Antibodies (Abs) and enzymes are structural and functional relatives. Abs with promiscuous peptidase activity are ubiquitous in healthy humans, evidently derived from germline variable domain immunoglobulin genes encoding the serine protease-like nucleophilic function. Exogenous and endogenous electrophilic antigens can bind the nucleophilic sites covalently, and recent evidence suggests that immunization with such antigens can induce proteolytic antibodies. Previously, Ab catalytic activities have been linked to pathogenic autoimmune reactions, but recent studies indicate that proteolytic Abs may also serve beneficial functions. An example is the rapid and selective cleavage of the HIV-1 coat protein gp120 by IgMs found in uninfected humans. The selectivity of this reaction appears to derive from recognition of gp120 as a superantigen. A second example is the cleavage of amyloid beta-peptide by IgM and IgG from aged humans, a phenomenon that may represent a specific proteolytic response to a neurotoxic endogenous peptide implicated in the pathogenesis of Alzheimer's disease.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15633014     DOI: 10.1007/s00281-004-0191-1

Source DB:  PubMed          Journal:  Springer Semin Immunopathol        ISSN: 0344-4325


  81 in total

1.  Association between IgM response to IgG damaged by glyoxidation and disease activity in rheumatoid arthritis.

Authors:  M D Lucey; M M Newkirk; C Neville; K Lepage; P R Fortin
Journal:  J Rheumatol       Date:  2000-02       Impact factor: 4.666

2.  Proteolytic antibody light chains alter beta-amyloid aggregation and prevent cytotoxicity.

Authors:  Ruitian Liu; Chad McAllister; Yuri Lyubchenko; Michael R Sierks
Journal:  Biochemistry       Date:  2004-08-10       Impact factor: 3.162

3.  The fraud of Abderhalden's enzymes.

Authors:  U Deichmann; B Müller-Hill
Journal:  Nature       Date:  1998-05-14       Impact factor: 49.962

Review 4.  CD5+ B lymphocytes, polyreactive antibodies and the human B-cell repertoire.

Authors:  P Casali; A L Notkins
Journal:  Immunol Today       Date:  1989-11

Review 5.  The role of CD4 in HIV envelope-mediated pathogenesis.

Authors:  R F Siliciano
Journal:  Curr Top Microbiol Immunol       Date:  1996       Impact factor: 4.291

Review 6.  Catalytic antibodies in healthy humans and patients with autoimmune and viral diseases.

Authors:  G A Nevinsky; Valentina N Buneva
Journal:  J Cell Mol Med       Date:  2003 Jul-Sep       Impact factor: 5.310

7.  Site-directed mutagenesis of proteolytic antibody light chain.

Authors:  Q S Gao; M Sun; A R Rees; S Paul
Journal:  J Mol Biol       Date:  1995-11-10       Impact factor: 5.469

8.  Amidase activity of human Bence Jones proteins.

Authors:  K Matsuura; K Yamamoto; H Sinohara
Journal:  Biochem Biophys Res Commun       Date:  1994-10-14       Impact factor: 3.575

9.  Patients with Alzheimer disease have lower levels of serum anti-amyloid peptide antibodies than healthy elderly individuals.

Authors:  Marc E Weksler; Norman Relkin; Rimma Turkenich; Susan LaRusse; Ling Zhou; Paul Szabo
Journal:  Exp Gerontol       Date:  2002-07       Impact factor: 4.032

10.  The Ca2+ influx induced by beta-amyloid peptide 25-35 in cultured hippocampal neurons results from network excitation.

Authors:  J R Brorson; V P Bindokas; T Iwama; C J Marcuccilli; J C Chisholm; R J Miller
Journal:  J Neurobiol       Date:  1995-03
View more
  10 in total

Review 1.  Immunological origin and functional properties of catalytic autoantibodies to amyloid beta peptide.

Authors:  Sudhir Paul; Stephanie Planque; Yasuhiro Nishiyama
Journal:  J Clin Immunol       Date:  2010-05       Impact factor: 8.317

Review 2.  Beneficial catalytic immunity to abeta peptide.

Authors:  Sudhir Paul; Stephanie Planque; Yasuhiro Nishiyama
Journal:  Rejuvenation Res       Date:  2010 Apr-Jun       Impact factor: 4.663

3.  Crystal structure of a glycosylated Fab from an IgM cryoglobulin with properties of a natural proteolytic antibody.

Authors:  Paul A Ramsland; Simon S Terzyan; Gwendolyn Cloud; Christina R Bourne; William Farrugia; Gordon Tribbick; H Mario Geysen; Carolyn R Moomaw; Clive A Slaughter; Allen B Edmundson
Journal:  Biochem J       Date:  2006-05-01       Impact factor: 3.857

Review 4.  Back to the future: covalent epitope-based HIV vaccine development.

Authors:  Sudhir Paul; Stephanie Planque; Yasuhiro Nishiyama; Miguel Escobar; Carl Hanson
Journal:  Expert Rev Vaccines       Date:  2010-09       Impact factor: 5.217

Review 5.  Immunotherapy targeting pathological tau protein in Alzheimer's disease and related tauopathies.

Authors:  Einar M Sigurdsson
Journal:  J Alzheimers Dis       Date:  2008-10       Impact factor: 4.472

Review 6.  Catalytic antibodies to amyloid beta peptide in defense against Alzheimer disease.

Authors:  Hiroaki Taguchi; Stephanie Planque; Yasuhiro Nishiyama; Paul Szabo; Marc E Weksler; Robert P Friedland; Sudhir Paul
Journal:  Autoimmun Rev       Date:  2008-04-09       Impact factor: 9.754

7.  Diminished amyloid-beta burden in Tg2576 mice following a prophylactic oral immunization with a salmonella-based amyloid-beta derivative vaccine.

Authors:  Allal Boutajangout; Fernando Goni; Elin Knudsen; Fernanda Schreiber; Ayodeji Asuni; David Quartermain; Blas Frangione; Alejandro Chabalgoity; Thomas Wisniewski; Einar M Sigurdsson
Journal:  J Alzheimers Dis       Date:  2009       Impact factor: 4.472

Review 8.  Catalytic antibodies to HIV: physiological role and potential clinical utility.

Authors:  Stephanie Planque; Yasuhiro Nishiyama; Hiroaki Taguchi; Maria Salas; Carl Hanson; Sudhir Paul
Journal:  Autoimmun Rev       Date:  2008-04-29       Impact factor: 9.754

Review 9.  Catalytic Antibodies: Design, Expression, and Their Applications in Medicine.

Authors:  Daqun Zhao; Jie Chen; Xiaoyue Hu; Shujun Zhang
Journal:  Appl Biochem Biotechnol       Date:  2022-10-12       Impact factor: 3.094

10.  Plasma protein profiling of Mild Cognitive Impairment and Alzheimer's disease using iTRAQ quantitative proteomics.

Authors:  Fei Song; Anne Poljak; Nicole A Kochan; Mark Raftery; Henry Brodaty; George A Smythe; Perminder S Sachdev
Journal:  Proteome Sci       Date:  2014-01-17       Impact factor: 2.480

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.